Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Merrimack Pharmaceuticals Inc (MACK) Cancer Drugs Sold To Ipsen

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) has resolved to dispose of its cancer drugs unit to Ipsen. Some of these drugs include Doxil and Onivyde. The deal is worth close to $1.025 billion, with Onivyde alone expected to fetch approximately $800 million.

U.S. And Taiwan

While the US marketing rights of Onivyde are owned by Merrimack, in Taiwan the same are owned by PharmaEngine. Outside of the United States and Taiwan, the responsibility for developing and commercializing Onivyde lies with Shire PLC (NASDAQ:SHPG). In the deal, France-based Ipsen will get the rights to commercialize Onivyde in the United States as well as the rights to Doxil.

medication, pharmacist, shelf, care, pharmaceutical, medical, day, drug, clinic, medicament, drugstore, treatment, ill, smiling, medicine, pharmaceutics, of, hospital,


The exclusive licensing agreement that Merrimack has with Shire outside of the United States will remain, however. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) will still continue to get net milestone payments with regards to the development and commercialization rights to the tune of $33 million.

Following the deal, Merrimack will cut down on its employee numbers drastically. Over 80 percent of its employee base will be let go and the firm will remain with about 80 workers when the deal is completed in Q1 of 2017.

Special Cash Dividend

When broken down, the $1.025 billion that Merrimack will receive will comprise cash proceeds totaling $575 million that will emanate from cancer drug revenues. Merrimack will also get milestone payments totaling about $450 million. Shareholders will benefit from the cash proceeds as about $200 million will be paid out in a special cash dividend.

Gary Crocker, chairman and CEO of Merrimack, praised the decision saying it would be of maximum benefit to shareholders. Merrimack’s CEO also added that the firm wanted to concentrate on pipeline products MM-310, MM-141, and MM-121 as they were the programs that offered the most attractive returns on investment in the future.

In the recent past, Merrimack has been cash-strapped and the deal will offer a chance for the pharmaceutical firm to restructure and chart a new path. Just over two months ago, then-CEO Robert Mulroy quit, and the move was followed by the laying off of 22 percent of the workforce.

In Monday’s trading, shares of Merrimack Pharmaceuticals Inc (NASDAQ:MACK) rose by 1.94% to close the day at $3.64.

Follow Merrimack Pharmaceuticals Inc (NASDAQ:MACK)
Trade (NASDAQ:MACK) Now!

Note: This article is written by Andy Parker and was originally published at Market Exclusive.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
This is a FREE report from Insider Monkey. Credit Card is NOT required.